This patent had ► Log In grant time compared to others in this category.
Patent grant time can be influenced by many factors. Activities within the USPTO that are beyond the control of patent attornies can influence grant time, but short grant times can also indicate well-written patents and dedicated efforts to respond rapidly to USPTO office actions with strong arguments. Shorter grant times are preferable, and the scores for this section are inverse measures — higher scores are better.
This patent has ► Log In claims compared to others in this category.
The number of claims in a patent is correlated with its strength. Because greater claim counts increase the cost of a patent, more claims can indicate the importance an applicant assigns to a patent. Importantly, some may elect to file claims across multiple patents. A higher score in this metric indicates more claims, relative to others in this category.
This patent has received ► Log In citations from other patents, than others in this category.
Citations from other patents are an important measure of the significance of a patent. More citations indicate that other technologies build on a patent. Higher scores in this metric are better, and indicate more citations from other patents.
This patent referenced ► Log In citations to other patents, than others in this category.
A lower number of citations to other patents can be a sign of diminished patent strength. More citations indicate dependence on more other technologies. Higher scores in this category are better, and indicate fewer citations to other patents.
This patent has ► Log In proximity to basic research compared to others in this category.
Proximity to basic research is measured by comparing the number of citations to non-patent literature among a cohort of patents. Because most non-patent citations are primary research papers, a higher count indicates greater proximity to basic research.
|9,211,410||Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation|
|9,211,409||Methods and systems for reducing inflammation by neuromodulation of T-cell activity|
|9,174,041||Nerve cuff with pocket for leadless stimulator|
|9,162,064||Neural stimulation devices and systems for treatment of chronic inflammation|
|8,996,116||Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction|
|8,914,114||Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation|
|8,886,339||Nerve cuff with pocket for leadless stimulator|
|8,855,767||Neural stimulation devices and systems for treatment of chronic inflammation|
|8,788,034||Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation|
|8,722,631||Soluble tumor necrosis factor receptor treatment of medical disorders|
|8,612,002||Neural stimulation devices and systems for treatment of chronic inflammation|
|8,412,338||Devices and methods for optimizing electrode placement for anti-inflamatory stimulation|
|8,410,060||Soluble tumor necrosis factor receptor treatment of medical disorders|
|8,391,970||Devices and methods for inhibiting granulocyte activation by neural stimulation|
|8,119,605||Soluble tumor necrosis factor receptor treatment of medical disorders|
|8,093,216||Method of treating cancer by inhibition of p95HER-2 production|
|7,915,225||Soluble tumor necrosis factor receptor treatment of medical disorders|
|7,695,948||Antibodies that bind TNF-Î± converting enzyme|
|7,358,352||Nucleic acids encoding human TNF-Î± convertase|
|7,199,224||Antibodies that bind TNF-Î± converting enzyme|
|7,135,555||Mammalian TNF-Î± convertases|
|6,881,407||Method for treating hepatitis|
|6,797,820||Succinate compounds, compositions and methods of use and preparation|
|6,632,667||Modulation of L-selectin shedding via inhibition of tumor necrosis factor-| converting enzyme (TACE)|
|6,555,354||TNF-| converting enzyme|
|6,406,901||TNF-a converting enzyme|
|6,406,877||TNF-| converting enzyme|
|6,384,076||Inhibition or erythrocyte sickling by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester|
|6,307,101||Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use|
|6,180,403||Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression|
|5,929,278||Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use|
|5,853,977||Mammalian TNF-.alpha. convertases|
|5,834,435||Inhibition of TNF-.alpha. pleiotropic and cytotoxic effects|